NCT02079480View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Healthy Adult Volunteers
Interventions
DRUG

BMS-986090

DRUG

Placebo matching with BMS-986090

DRUG

Keyhole limpet hemocyanin

Trial Locations (2)

21225

Parexel Baltimore Early Phase Clinical Unit, Baltimore

91206

California Clinical Trials Medical Group, Glendale

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02079480 - Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects | Biotech Hunter | Biotech Hunter